Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Simple Cervical Cancer Exams Proposed for Low-Resource Settings

By Labmedica staff writers
Posted on 12 Mar 2008
Cervical cancer, caused by the human papillomavirus (HPV), affects about 500,000 women each year and kills 270,000 worldwide annually. More...
There is a huge discrepancy between cervical cancer deaths in rich and poor nations--80-85% of deaths occur in the developing world. In developed countries, screening programs using the Pap smear are in place to spot disease and treat it early. However, a successful Pap testing program requires a high degree of organization, sophisticated laboratory equipment, and highly trained technicians. In spite of government efforts, large-scale Pap screening programs have failed in poorer regions.

During a panel presentation at the Goethe-Institut (Washington, DC, USA) on March 5, 2008, Dr. Jacqueline Sherris of PATH (formally: Program for Appropriate Technology in Health), an Alliance for Cervical Cancer Prevention (ACCP) founder, noted, "cervical cancer represents a huge global inequity with a heavy burden on poor women.”

A painless visual screening method has been found to be as effective, if not more effective, as the Pap smear. For the visual screening method, a trained health worker swabs the patient's cervix with vinegar. After one minute, any small lesions on the cervix--signs of potential future cancer--can be seen with the naked eye.

"In most cases it is possible to treat women for precancer during the same visit to the clinic,” said Dr. Harshad Sanghvi of the Johns Hopkins Program for International Education in Gynecology and Obstetrics (JHPIEGO; Baltimore, MD, USA), an ACCP partner. "This is important because if a woman is sent home the day of the exam and asked to come back days or weeks later to hear the results and be treated, she may not be able to return. In the past, many women have missed the care they needed for this reason. Treatment in the late stages of cervical cancer--when women suffer symptoms--is difficult and often not successful. We need to screen all women, beginning at age 30, and provide rapid treatment to those who need it,” Dr. Sanghvi added.

Dr. R. Sankaranarayanan, from the International Agency for Research on Cancer (IARC; Lyons, France), has studied alternatives to Pap smear screening in India and other countries. He explained that cervical cancer is easy to treat if precancerous signs are detected early. Treatment in low-resource settings often can be implemented using a device that destroys the affected tissue by freezing, the same way that common warts are frozen.

"New technologies for cervical cancer prevention are revolutionizing public health,” stated Silvana Luciani of the Pan American Health Organization (PAHO; Washington, DC, USA). "Visual screening methods, high-tech DNA tests for HPV, and the new HPV vaccines represent incredible opportunities to strengthen prevention. We need to protect girls from HPV infection with vaccine, but immunization is not a substitute for screening.

Screening programs are needed to care for women who may have already been infected with HPV, because the vaccine does not protect them effectively and there are cancer-causing types of HPV not targeted by the vaccine. Research indicates that a combination of vaccination and screening can dramatically reduce cervical cancer deaths in the coming decades.”


Related Links:
Goethe-Institut
Johns Hopkins Program for International Education in Gynecology and Obstetrics
International Agency for Research on Cancer

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.